000 | 01788 a2200517 4500 | ||
---|---|---|---|
005 | 20250516125837.0 | ||
264 | 0 | _c20130312 | |
008 | 201303s 0 0 eng d | ||
022 | _a1942-5546 | ||
024 | 7 |
_a10.1016/j.mayocp.2012.11.003 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBundrick, John B | |
245 | 0 | 0 |
_aClinical pearls in general internal medicine 2012. _h[electronic resource] |
260 |
_bMayo Clinic proceedings _cJan 2013 |
||
300 |
_a106-12 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Journal Article | ||
650 | 0 | 4 |
_aAbdominal Pain _xdiagnosis |
650 | 0 | 4 | _aAdministration, Intranasal |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAtrial Fibrillation _xcomplications |
650 | 0 | 4 | _aBone Density |
650 | 0 | 4 |
_aBronchodilator Agents _xadministration & dosage |
650 | 0 | 4 |
_aCommon Cold _xdrug therapy |
650 | 0 | 4 | _aDiagnosis, Differential |
650 | 0 | 4 |
_aDry Eye Syndromes _xdrug therapy |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFish Oils _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInternal Medicine _xeducation |
650 | 0 | 4 |
_aIpratropium _xadministration & dosage |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNasal Decongestants _xadministration & dosage |
650 | 0 | 4 |
_aNocturia _xetiology |
650 | 0 | 4 |
_aOsteoporosis _xcomplications |
650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xdiagnosis |
650 | 0 | 4 |
_aOxymetazoline _xadministration & dosage |
650 | 0 | 4 |
_aRisk Assessment _xmethods |
650 | 0 | 4 |
_aSleep Apnea, Obstructive _xcomplications |
650 | 0 | 4 |
_aStroke _xetiology |
650 | 0 | 4 | _aTime Factors |
700 | 1 | _aLitin, Scott C | |
773 | 0 |
_tMayo Clinic proceedings _gvol. 88 _gno. 1 _gp. 106-12 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.mayocp.2012.11.003 _zAvailable from publisher's website |
999 |
_c22378524 _d22378524 |